Clinical Cancer Research Prevention Award Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 14, 1649, March 15, 2008. doi: 10.1158/1078-0432.CCR-07-2218
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Orlowski, R. Z.
Right arrow Articles by Kuhn, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orlowski, R. Z.
Right arrow Articles by Kuhn, D. J.
Related Collections
Right arrow Therapeutics and Targets
Right arrow Therapeutics and Targets: Experimental Therapeutics– Small Molecules
Right arrow Clinical Research: Clinical Trials

Focus Section

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

Robert Z. Orlowski1,2 and Deborah J. Kuhn1

Authors' Affiliations: Departments of 1 Lymphoma/Myeloma and 2 Experimental Therapeutics, Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Robert Z. Orlowski, The University of Texas M. D. Anderson Cancer Center, Department of Lymphoma/Myeloma, 1515 Holcombe Boulevard, Unit 429, Houston, TX 77030. Phone: 713-792-2860; Fax: 713-563-5067; E-mail: rorlowsk{at}mdanderson.org.

Abstract

The ubiquitin-proteasome pathway is involved in intracellular protein turnover, and its function is crucial to cellular homeostasis. First synthesized as probes of proteolytic processes, proteasome inhibitors began to be thought of as potential drug candidates when they were found to induce programmed cell death preferentially in transformed cells. They made their first leap into the clinic to be tested as therapeutic agents 10 years ago, and since then, great strides have been made in defining their mechanisms of action, their clinical efficacy and toxicity, and some of their limitations in the form of resistance pathways. Validation of the ubiquitin-proteasome pathway as a target for cancer therapy has come in the form of approvals of the first such inhibitor, bortezomib, for relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this agent has become a standard of care. Lessons learned from this first-in-class agent are now being applied to the development of a new generation of proteasome inhibitors that hold the promise of efficacy in bortezomib-resistant disease and possibly in a broader spectrum of diseases. This saga provides a salient example of the promise of translational medicine and a paradigm by which other agents may be successfully brought from the bench to the bedside.




This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
T.-M. Yang, D. Barbone, D. A. Fennell, and V. C. Broaddus
Bcl-2 Family Proteins Contribute to Apoptotic Resistance in Lung Cancer Multicellular Spheroids
Am. J. Respir. Cell Mol. Biol., July 1, 2009; 41(1): 14 - 23.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Nojima, R. Maruyama, H. Yasui, H. Suzuki, Y. Maruyama, I. Tarasawa, Y. Sasaki, H. Asaoku, H. Sakai, T. Hayashi, et al.
Genomic Screening for Genes Silenced by DNA Methylation Revealed an Association between RASD1 Inactivation and Dexamethasone Resistance in Multiple Myeloma
Clin. Cancer Res., July 1, 2009; 15(13): 4356 - 4364.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. A. Soucy, P. G. Smith, and M. Rolfe
Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer
Clin. Cancer Res., June 15, 2009; 15(12): 3912 - 3916.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Dunleavy, S. Pittaluga, M. S. Czuczman, S. S. Dave, G. Wright, N. Grant, M. Shovlin, E. S. Jaffe, J. E. Janik, L. M. Staudt, et al.
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
Blood, June 11, 2009; 113(24): 6069 - 6076.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. J. Kuhn, S. A. Hunsucker, Q. Chen, P. M. Voorhees, M. Orlowski, and R. Z. Orlowski
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
Blood, May 7, 2009; 113(19): 4667 - 4676.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. Delmonte, M. Ghielmini, and C. Sessa
Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas
Oncologist, May 1, 2009; 14(5): 511 - 525.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
M. IIJIMA, I. MOMOSE, and D. IKEDA
TP-110, a New Proteasome Inhibitor, Down-regulates IAPs in Human Multiple Myeloma Cells
Anticancer Res, April 1, 2009; 29(4): 977 - 985.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
R. C Smallridge, L. A Marlow, and J. A Copland
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
Endocr. Relat. Cancer, March 1, 2009; 16(1): 17 - 44.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
J. Ruan, K. Hajjar, S. Rafii, and J. P. Leonard
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma
Ann. Onc., March 1, 2009; 20(3): 413 - 424.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Dayal, A. Sparks, J. Jacob, N. Allende-Vega, D. P. Lane, and M. K. Saville
Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53
J. Biol. Chem., February 20, 2009; 284(8): 5030 - 5041.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Pagnan, D. Di Paolo, R. Carosio, F. Pastorino, D. Marimpietri, C. Brignole, A. Pezzolo, M. Loi, L. J.V. Galietta, F. Piccardi, et al.
The Combined Therapeutic Effects of Bortezomib and Fenretinide on Neuroblastoma Cells Involve Endoplasmic Reticulum Stress Response
Clin. Cancer Res., February 15, 2009; 15(4): 1199 - 1209.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Bisping, D. Wenning, M. Kropff, D. Gustavus, C. Muller-Tidow, M. Stelljes, G. Munzert, F. Hilberg, G. J. Roth, M. Stefanic, et al.
Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3-Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma
Clin. Cancer Res., January 15, 2009; 15(2): 520 - 531.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
P. G. Richardson, C. Mitsiades, J. Laubach, D. Chauhan, T. Hideshima, and K. Anderson
Realizing the Anticancer Potential of Proteasome Inhibition: The Clinical Development of Bortezomib and Second-generation Proteasome Inhibitors
ASCO Educational Book, January 1, 2009; 2009(1): 163 - 170.
[Abstract] [Full Text] [PDF]


Home page
GeneticsHome page
X. Wang, H. Xu, D. Ju, and Y. Xie
Disruption of Rpn4-Induced Proteasome Expression in Saccharomyces cerevisiae Reduces Cell Viability Under Stressed Conditions
Genetics, December 1, 2008; 180(4): 1945 - 1953.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Plesca, S. Mazumder, V. Gama, S. Matsuyama, and A. Almasan
A C-terminal Fragment of Cyclin E, Generated by Caspase-mediated Cleavage, Is Degraded in the Absence of a Recognizable Phosphodegron
J. Biol. Chem., November 7, 2008; 283(45): 30796 - 30803.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Oerlemans, N. E. Franke, Y. G. Assaraf, J. Cloos, I. van Zantwijk, C. R. Berkers, G. L. Scheffer, K. Debipersad, K. Vojtekova, C. Lemos, et al.
Molecular basis of bortezomib resistance: proteasome subunit {beta}5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Blood, September 15, 2008; 112(6): 2489 - 2499.
[Abstract] [Full Text] [PDF]


Home page
CRO ContentHome page
G. C. Prendergast
Refining Cytotoxic Therapy: Progress in Generalized Therapeutics for Cancer
Cancer Reviews Online Content, April 1, 2008; 2008(4): 7 - 7.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.